Eagle Nuclear Energy Corp. financials

NUCL CIK 0002089283

Source: EDGAR filings · Built 2026-10-14T23:58:52Z

Custom taxonomy namespace: ffd

Key metrics by reporting period

Up to six most-recent periods side-by-side. Rows are the curated key lines — revenue, margins, cash, debt, equity, cash-flow totals, plus the derived and valuation metrics we compute on top. For every tag a filer reported in one period, use the single-filing drilldown below.

Derived Metrics

Concept Q3 2026Q2 2026Q1 2026Q1 2026Q3 2026Q2 2026
Free Cash Flow -7.40M -4.76M -1.61M — — —
Working Capital 24.92M 27.16M 30.70M 621.31K — —
Net Debt -24.77M -27.36M -30.53M -1.21M — —
Return on Equity (ROE) -190.96% 359.04% -10.20% — -32.26% -19.49%
Return on Assets (ROA) 10.80% -58.16% -3.23% — — —
Current Ratio 20.69× 15.88× 39.44× 1.74× — —
Debt-to-Equity -0.30× -0.10× 0.05× 0.05× — —
Cash Conversion Ratio -1.69× 0.19× 1.07× — 2.70× 1.90×
Accruals Ratio 0.29× -0.47× 0.00× — — —
CapEx Coverage -133.83× -98.23× -36.44× — — —
Free Cash Flow Per Share — $-0.16 $-0.08 — — —

Income Statement

Concept Q3 2026Q2 2026Q1 2026Q1 2026Q3 2026Q2 2026
Operating Expenses 3.72M 7.31M 1.46M — 1.28M 1.02M
Net Income (Loss) Attributable to Parent 4.35M -25.06M -1.47M — -1.28M -1.03M
Earnings Per Share, Basic — $-0.87 $-0.08 — — $-0.06
Weighted Average Number of Shares Outstanding, Basic — 29.66M 19.36M — — 17.72M
Earnings Per Share, Diluted — $-0.87 $-0.08 — — $-0.06
Weighted Average Number of Shares Outstanding, Diluted — 29.66M 19.36M — — 17.72M

Balance Sheet

Concept Q3 2026Q2 2026Q1 2026Q1 2026Q3 2026Q2 2026
Assets, Current 26.18M 28.99M 31.50M 1.46M — —
Assets 40.25M 43.09M 45.57M 2.89M — —
Liabilities, Current 1.27M 1.83M 798.77K 843.52K — —
Liabilities 15.66M 24.34M 5.60M 898.61K — —
Stockholders' Equity Attributable to Parent -2.28M -6.98M 14.43M 1.69M 3.98M 5.26M
Common Stock, Shares, Outstanding — 29.58M 29.58M 18.89M — —

Cash Flow Statement

Concept Q3 2026Q2 2026Q1 2026Q1 2026Q3 2026Q2 2026
Net Cash Provided by (Used in) Operating Activities -7.34M -4.71M -1.57M — -3.46M -1.94M
Payments to Acquire Property, Plant, and Equipment 54.85K 47.97K 43.06K — — —
Net Cash Provided by (Used in) Investing Activities 35.79K 63.22K 69.35K — -841.08K -600.00K
Net Cash Provided by (Used in) Financing Activities 31.68M 31.64M 31.64M — 7.74M 7.44M

Raw XBRL tagging for a single filing

Every us-gaap and custom concept the filer tagged for one fiscal period, grouped by statement. Start here when a number in the trend table above surprises you and you want to see the exact tag behind it. Derived and valuation rows are omitted here because they already appear in the trend table.

Most recent filing shown by default.

Compare filings side-by-side

Diff any two filings with deltas and added / removed tags.

Immaterial rows are USD line items under 1% of the period's revenue — the noise floor below which a single tag rarely moves the investment thesis. Revenue is read from the filer's top-line concept (Revenues / RevenueFromContractWithCustomerExcludingAssessedTax, with a fallback chain). Non-USD rows, rows without a numeric value, and every row on a filing with no identifiable revenue anchor stay visible. Flip the switch off to see every tag the filer reported for the period.

Loading filing details…

Methodology

All facts on this page come straight from SEC EDGAR XBRL company-facts filings (NUCL CIK 0002089283), grouped by financial statement using FASB's base us-gaap presentation taxonomy. Filers may re-parent concepts onto different statements in their own extension taxonomy, so a handful of rows can show up under a different statement than on the actual 10-K / 10-Q; custom concepts and any we couldn't map fall into Other. Hover a cell to see the fully-qualified concept name and the filer's description.

For the full methodology — statement grouping, the Other bucket, derived metrics, and fact tooltips — see the methodology reference for the statement grouping, the "Other" bucket, derived metrics, and fact tooltips.

Related tickers

DDOG

Datadog, Inc.

MRDN

Meridian Holdings Inc./NV

UTHR

United Therapeutics Corporation